These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 29409313)
1. The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era. Jin YN; Zhang WJ; Cai XY; Li MS; Lawrence WR; Wang SY; Mai DM; Du YY; Luo DH; Mo HY Cancer Res Treat; 2019 Jan; 51(1):34-42. PubMed ID: 29409313 [TBL] [Abstract][Full Text] [Related]
2. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis. Chen J; Ding J; Xu Y; Hong H; Lin X; Xu M; Yan L; Xu T; Fei Z; Chen C J Geriatr Oncol; 2023 Nov; 14(8):101648. PubMed ID: 37897887 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers. Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648 [TBL] [Abstract][Full Text] [Related]
4. Impact of comorbidity on tolerability and survival following curative intent intensity modulated radiotherapy in older patients with nasopharyngeal cancer. Sommat K; Yit NLF; Wang F; Lim JHC J Geriatr Oncol; 2018 Jul; 9(4):352-358. PubMed ID: 29429963 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study. Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080 [TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and prognosis of elderly nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Lyu Y; Ni M; Zhai R; Kong F; Du C; Hu C; Ying H Eur Arch Otorhinolaryngol; 2021 Jul; 278(7):2549-2557. PubMed ID: 33021689 [TBL] [Abstract][Full Text] [Related]
7. Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy: A propensity score-matched analysis. Li Y; Guan X; Xing X; Hu C Head Neck; 2024 Jul; 46(7):1766-1776. PubMed ID: 38591178 [TBL] [Abstract][Full Text] [Related]
8. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Li PJ; Mo HY; Luo DH; Hu WH; Jin T Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698 [TBL] [Abstract][Full Text] [Related]
11. Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance. Wang J; Huang X; Sun S; Wang K; Qu Y; Chen X; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Xiao J; Gao L; Xu G; Hu C; Li YX; Yi J Cancer Med; 2021 Jun; 10(11):3613-3621. PubMed ID: 33960136 [TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiotherapy for elderly patients with nasopharyngeal carcinoma. Cao C; Hu Q; Chen X Head Neck; 2018 Mar; 40(3):590-595. PubMed ID: 29155480 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era. Niu X; Xue F; Liu P; Hu C; He X Int J Med Sci; 2022; 19(2):267-273. PubMed ID: 35165512 [No Abstract] [Full Text] [Related]
14. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193 [TBL] [Abstract][Full Text] [Related]
15. Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study. Liu F; Luo T; Jin T; Zhang J; Xiang Z; Yan R; Xie L; Wu X; Zhang H; Wang F; Li P; Liu L BMC Cancer; 2019 Jun; 19(1):554. PubMed ID: 31176358 [TBL] [Abstract][Full Text] [Related]
16. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Yao JJ; Qi ZY; Liu ZG; Jiang GM; Xu XW; Chen SY; Zhu FT; Zhang WJ; Lawrence WR; Ma J; Zhou GQ; Sun Y Radiother Oncol; 2019 Aug; 137():137-144. PubMed ID: 31102988 [TBL] [Abstract][Full Text] [Related]
17. The prognostic value of the ratio of neutrophils to lymphocytes before and after intensity modulated radiotherapy for patients with nasopharyngeal carcinoma. Liu J; Wei C; Tang H; Liu Y; Liu W; Lin C Medicine (Baltimore); 2020 Jan; 99(2):e18545. PubMed ID: 31914029 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma. Hu J; Huang Q; Gao J; Guan X; Hu W; Yang J; Qiu X; Chen M; Kong L; Lu JJ Cancer; 2020 Dec; 126(23):5173-5183. PubMed ID: 32931035 [TBL] [Abstract][Full Text] [Related]
19. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis. Huang XD; Zhou GQ; Lv JW; Zhou HQ; Zhong CW; Wu CF; Zheng ZQ; He XJ; Peng L; Ma J; Sun Y Radiother Oncol; 2018 Nov; 129(2):389-395. PubMed ID: 30270098 [TBL] [Abstract][Full Text] [Related]
20. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. Huang CL; Guo R; Li JY; Xu C; Mao YP; Tian L; Lin AH; Sun Y; Ma J; Tang LL Eur Radiol; 2020 Feb; 30(2):816-822. PubMed ID: 31650266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]